To investigate how physicians felt about HRT use in breast cancer survivors a half year after the WHI trial. Methods: In December 2002, a questionnaire was conducted in Flanders (Belgium). The survey contained a prese...To investigate how physicians felt about HRT use in breast cancer survivors a half year after the WHI trial. Methods: In December 2002, a questionnaire was conducted in Flanders (Belgium). The survey contained a presentation of a 35- year-old breast cancer survivor who presented with climacteric symptoms after treatment with tamoxifen. Results: With a response rate of 33.65% , a majority of the physicians did not prescribe classical oral HRT (5.40% ) in this patient. Physicians prefer to prescribe tibolone (30.68% ) or other alternative treatment (50.00% ). The main reason was the fear for increased recurrence of breast cancer. Furthermore the WHI oestrogen plus progestin trial and its attention in the media, a half year prior to the survey, influenced one-third of the physician’s prescribing attitude. Conclusions: Two-thirds of the physicians did not change prescribing attitude after the WHI oestrogen plus progestin trial. HRT is a well proven effective treatment in breast cancer survivors with severe climacteric complaints, but a majority of physicians is not convinced of its safety in breast cancer survivors. Therefore, a majority of physicians do not find the need to prescribe HRT in breast cancer survivors.展开更多
There is not only a need for scientific data regarding the risk of recurrence of breast cancer by starting hormone replacement therapy (HRT) but also regarding the patients’ needs for HRT. Objectives: To examine the ...There is not only a need for scientific data regarding the risk of recurrence of breast cancer by starting hormone replacement therapy (HRT) but also regarding the patients’ needs for HRT. Objectives: To examine the severity of climacteric complaints in breast cancer patients and to examine if they are willing to take HRT. Methods: In November 2003, a questionnaire was sent to 469 breast cancer survivors. The survey examined on a scale base the severity of climacteric complaints and the patient’s opinion on starting HRT. Results: More than 76% of the patients complained that they experience or had experienced hot flushes or night sweating. More than half (53% ) of this group found the inconvenience severe to extreme, affecting the patient’s quality of life. A majority (80.5% ) patients who had already taken HRT, found that it improved their quality of life substantially. When the results of observational studies were explained regarding HRT in breast cancer survivors, a majority said they would take or would consider taking HRT (57.9% ). Conclusion: While physicians are more reserved in prescribing HRT in breast cancer survivors, a combination of severe symptomatic climacteric complaints and the willingness of the patient to be treated should at least result in a “ consideration” of prescribing HRT.展开更多
文摘To investigate how physicians felt about HRT use in breast cancer survivors a half year after the WHI trial. Methods: In December 2002, a questionnaire was conducted in Flanders (Belgium). The survey contained a presentation of a 35- year-old breast cancer survivor who presented with climacteric symptoms after treatment with tamoxifen. Results: With a response rate of 33.65% , a majority of the physicians did not prescribe classical oral HRT (5.40% ) in this patient. Physicians prefer to prescribe tibolone (30.68% ) or other alternative treatment (50.00% ). The main reason was the fear for increased recurrence of breast cancer. Furthermore the WHI oestrogen plus progestin trial and its attention in the media, a half year prior to the survey, influenced one-third of the physician’s prescribing attitude. Conclusions: Two-thirds of the physicians did not change prescribing attitude after the WHI oestrogen plus progestin trial. HRT is a well proven effective treatment in breast cancer survivors with severe climacteric complaints, but a majority of physicians is not convinced of its safety in breast cancer survivors. Therefore, a majority of physicians do not find the need to prescribe HRT in breast cancer survivors.
文摘There is not only a need for scientific data regarding the risk of recurrence of breast cancer by starting hormone replacement therapy (HRT) but also regarding the patients’ needs for HRT. Objectives: To examine the severity of climacteric complaints in breast cancer patients and to examine if they are willing to take HRT. Methods: In November 2003, a questionnaire was sent to 469 breast cancer survivors. The survey examined on a scale base the severity of climacteric complaints and the patient’s opinion on starting HRT. Results: More than 76% of the patients complained that they experience or had experienced hot flushes or night sweating. More than half (53% ) of this group found the inconvenience severe to extreme, affecting the patient’s quality of life. A majority (80.5% ) patients who had already taken HRT, found that it improved their quality of life substantially. When the results of observational studies were explained regarding HRT in breast cancer survivors, a majority said they would take or would consider taking HRT (57.9% ). Conclusion: While physicians are more reserved in prescribing HRT in breast cancer survivors, a combination of severe symptomatic climacteric complaints and the willingness of the patient to be treated should at least result in a “ consideration” of prescribing HRT.
